Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol (GnRH)
Infertility
About this trial
This is an interventional treatment trial for Infertility focused on measuring GnRH antagonist, fixed protocol, flexible protocol
Eligibility Criteria
Inclusion Criteria:
- Have an indication for COS and IVF/ICSI;
- be <35 years old;
- have a BMI of 18-25kg/m2;
- have a regular menstruation with a range of 24-35 days;
fulfill one of these three criteria as follow:
- the number of oocytes retrieved>15 in previous COS cycle;
- Serum AMH (examined on the menstrual cycle day 2)>3.52ng/ml;
- antral follicle count (AFC) (examined by ultrasonic on the menstrual cycle day 2)>16
- have willingness to give informed consent
Exclusion Criteria:
- Presence of unilateral ovary absence;
- Any difficulty on oocyte pick-up with abnormal condition of ovary and pelvic cavity;
- Women have any clinically relevant pathology could impair embryo implantation or pregnancy continuation (uterine malformation, intermural uterine fibroids>3cm, intrauterine adhesion,etc);
- Women with polycystic ovary syndrome (PCOS) diagnosed by Rotterdam consensus criterion(Rotterdam, 2004)
- Other known abnormal ovulation disorders (including but not limited to adrenal gland disease, thyroid disease and hyperprolactinemia);
- A history of recurrent miscarriage or previous IVF cycles failure>2;
- A history of ovarian hypo-response in previous ovarian stimulation;
- Women with other clinical/socio-economic factors precluding the completion of the study at the discretion of the investigator.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Other
Other
Fixed Protocol
Flexible protocol
Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start fixedly on stimulation Day 5. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start flexibly by the promissory criterion in the flexible group. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk